DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
Tweet Send to a Friend
DARA BioSciences, Inc. (Nasdaq: DARA) presented clinical data results for KRN5500, its lead compound for Neuropathic Pain, which achieved its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
